iMAgery Focused Therapy for PSychosis (iMAPS-2): An Assessor-blind Feasibility Randomized Controlled Clinical Trial
Schizophrenia Bulletin · 2025
DOI: 10.1093/schbul/sbaf060 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Schizophrenia Bulletin, 2025. Verfasst von Christopher D J Taylor und 18 weiteren Autor:innen. Beteiligte Einrichtung: School of Psychology, Faculty of Science, The University of Sheffield, Sheffield, United Kingdom. Hauptthemen laut MEDLINE: Psychotic Disorders, Imagery, Psychotherapy, Hallucinations, Delusions. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Department of Health and Social Care.
Abstract (Originalsprache)
Background and Hypothesis Intrusive mental images and negative schematic beliefs have been identified as maintenance and possible causal factors for some psychotic experiences, with limited focus in existing therapies in psychosis. Our primary aim was to assess the feasibility and acceptability of undertaking a randomized controlled trial (RCT) of a novel, imagery focused psychological therapy for psychosis (iMAPS). Study Design An assessor-blind RCT (iMAPS-2). Participants who were help seeking; with hallucinations or delusions, who reported distressing intrusive mental imagery were eligible to take part. Participants were randomly assigned (2:1) to receive 12 sessions of iMAPS therapy plus standard care or treatment as usual (TAU). Assessments were undertaken at 0, 16 and 28 weeks. The primary feasibility outcomes were recruitment target, retention at 16 week follow up and number of therapy sessions attended. Study Results The trial recruitment was 100% of target (45 participants). The study had a high rate of retention of 80% (36 participants) at 16-week primary endpoint, a high rate of adherence to the imagery focused therapy (77%) and positive qualitative feedback. There were two serious adverse events in the iMAPS therapy arm deemed unrelated to treatment and zero in the TAU group. Conclusions This is the largest trial to date of imagery focused therapy for psychosis, demonstrating it is safe. An adequately powered clinical and cost effectiveness trial is warranted to provide an estimate of the effects of the iMAPS therapy. Trial Registration ISRCTN 81150786.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Psychology, Faculty of Science, The University of Sheffield, Sheffield, United Kingdom.
- Pennine Care NHS Foundation Trust, Greater Manchester, United Kingdom.
- Lancashire Clinical Trials Unit, University of Central Lancashire, Preston, United Kingdom.
- School of Health & Social Care, Edinburgh Napier University, Edinburgh, United Kingdom.
- Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom.
- Division of Psychology and Mental Health, School of Health Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom.
ORCID-Profile: Christopher D J Taylor
Förderung
- National Institute for Health and Care Research
- Department of Health and Social Care
Zitieren
APA
Taylor, C. D. J., Helliwell, B., Coleman, R., Sutton, C. J., Hutton, P., Sylvestre, Y., Bird, L., Shields, G., Kelly, J. A., Brandwood-Spencer, T., Boland, A., Sharrock-Ingham, E., Babatunde, B., Beech, A., Vikram, A., Guillemard, S., Arntz, A., Harper, S. F., & Berry, K. (2025). iMAgery Focused Therapy for PSychosis (iMAPS-2): An Assessor-blind Feasibility Randomized Controlled Clinical Trial. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbaf060
Vancouver
Taylor CDJ, Helliwell B, Coleman R, Sutton CJ, Hutton P, Sylvestre Y, et al. iMAgery Focused Therapy for PSychosis (iMAPS-2): An Assessor-blind Feasibility Randomized Controlled Clinical Trial. Schizophrenia Bulletin. 2025. doi:10.1093/schbul/sbaf060
BibTeX
@article{Taylor2025,
author = {Taylor, Christopher D J and Helliwell, Ben and Coleman, Rebecca and Sutton, Chris J and Hutton, Paul and Sylvestre, Yvonne and Bird, Leanne and Shields, Gemma and Kelly, James A and Brandwood-Spencer, Thomas and Boland, Alicia and Sharrock-Ingham, Emma and Babatunde, Bukunmi and Beech, Amy and Vikram, Anvita and Guillemard, Serena and Arntz, Arnoud and Harper, Sean F and Berry, Katherine},
title = {iMAgery Focused Therapy for PSychosis (iMAPS-2): An Assessor-blind Feasibility Randomized Controlled Clinical Trial},
journal = {Schizophrenia Bulletin},
year = {2025},
doi = {10.1093/schbul/sbaf060}
}
EUVIMED